^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Non-Small Cell Squamous Cancer

    Related cancers:
    1d
    SCORACLE: Real-Time Imaging to Improve Lung Cancer Diagnosis : Comparing Confocal Laser Endomicroscopy (CLE) With Standard Biopsy for Quicker and Safer Detection of Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P=N/A, N=70, Recruiting, Central Hospital, Nancy, France
    New trial
    2d
    Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer (clinicaltrials.gov)
    P=N/A, N=28, Not yet recruiting, Tang-Du Hospital
    New trial
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed • Qibeian (iparomlimab/tuvonralimab)
    2d
    Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, Jonsson Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • MET overexpression • EGFR exon 20 mutation
    |
    CONFIRM anti-Total c-MET (SP44) Rabbit Monoclonal Primary Antibody • VENTANA® MET (SP44) RxDx Assay
    |
    Tagrisso (osimertinib) • Emrelis (telisotuzumab vedotin-tllv)
    2d
    RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) (clinicaltrials.gov)
    P3, N=574, Recruiting, RemeGen Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • Aidixi (disitamab vedotin)
    6d
    PSI-Immune: Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (clinicaltrials.gov)
    P2, N=880, Recruiting, Diwakar Davar | N=480 --> 880
    Enrollment change
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TMB-H • MSI-H/dMMR
    |
    Keytruda (pembrolizumab)
    7d
    A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers (clinicaltrials.gov)
    P1/2, N=398, Recruiting, Hummingbird Bioscience | N=98 --> 398 | Trial completion date: Mar 2026 --> Dec 2027 | Trial primary completion date: Mar 2026 --> Dec 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Erbitux (cetuximab) • docetaxel • HMBD-001
    7d
    ITIL-306 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=1, Terminated, Instil Bio | N=51 --> 1 | Trial completion date: Nov 2039 --> Mar 2026 | Active, not recruiting --> Terminated; The study was terminated early due to discontinuation of development of the investigational program
    Enrollment change • Trial completion date • Trial termination
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    cyclophosphamide • fludarabine IV • ITIL-306
    7d
    QUILT2023: Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=102, Terminated, ImmunityBio, Inc. | N=1538 --> 102 | Trial completion date: Dec 2026 --> Oct 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2026 --> Oct 2025; There are no longer active subjects on QUILT-2.023. Data will be entered into clinicaltrials.gov within 1 year of the primary completion date.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    PD-L1 expression • EGFR mutation • BRAF mutation • ALK translocation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Anktiva (nogapendekin alfa inbakicept-pmln)
    8d
    ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC (clinicaltrials.gov)
    P3, N=494, Not yet recruiting, ImmunityBio, Inc.
    New P3 trial • IO biomarker
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Anktiva (nogapendekin alfa inbakicept-pmln)
    8d
    INTerpath-13: A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) (clinicaltrials.gov)
    P2, N=180, Recruiting, Merck Sharp & Dohme LLC | N=59 --> 180
    Enrollment change • Trial initiation date
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • intismeran autogene (mRNA-4157)
    13d
    Phase 1 Study of PF-08046033 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=250, Not yet recruiting, Pfizer
    New P1 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    13d
    Phase Ib of L-NMMA and Pembrolizumab (clinicaltrials.gov)
    P1, N=12, Completed, The Methodist Hospital Research Institute | Active, not recruiting --> Completed
    Trial completion • Mismatch repair • Tumor mutational burden • IO biomarker • MSI-H • dMMR
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    PD-L1 expression • TMB-H • MSI-H/dMMR • BRAF mutation
    |
    Keytruda (pembrolizumab) • tilarginine (L-NMMA)